For AHIT® and urexent®, FBM-PHARMA has been able to increase its sales revenues in recent months due to targeted addressing of already active medical doctors.
Negotiations with collection centres in North Rhine-Westphalia and Saarland are well advanced, the necessary agreements are in the final vote. Thus, the FBM PHAMRA can immediately leave their first footprint on the map with respect to the procurement of autologous blood and blood components for the production of autologous serum eye drops (ASAT).
As planned, VCC Medical had submitted the application in the second round of funding scheduled for the end of October as part of the "Horizon 2020" program. However, the European Commission recently requested a further update of the submission documents, which the VCC Medical Group will implement as requested in the upcoming weeks.
A key element in improving Reniale® is to demonstrate the biological effectiveness of Reniale®.
While the scientific work on Reniale is being pursued within the limits of the company's financial capabilities, management's focus is on raising capital.